At T2DXX, our goal is to share the voice of the T2 person, the authentic lived experience. One of the ways T2DXX does this is through submissions to the Canadian Agency For Drugs And Technologies In Health.    CADTH is a not-for-profit organization responsible for providing health care decision-makers with objective evidence to help make informed decisions about the optimal use of health technologies. This includes drugs, medical devices (including dental and surgical), procedures, and diagnostic tests. They help shape the landscape of our healthcare system to benefit patients.    Your input has and will continue to influence health care decision-makers to make informed decisions about new products that enter the market.  Over the past two years, we've made two large submissions to this agency with your help. We'll continue to make submissions focusing on your experiences. Currently, there are only two patient groups in Canada that make submissions to this agency, Diabetes Canada, and us, the Type 2 Diabetes Experience Exchange. Our submission stands out in that we collected actual experiences using the drugs and focusing on the financial and psychosocial impact of managing a chronic illness.    OUR FIRST COMMON DRUG REVIEW Insulin degludec + liraglutide (trademark name Xultophy® )   BACKGROUND INFORMATION Xultophy®  combines two medications together in one injection - insulin degludec and liraglutide.   Insulin degludec is a long-acting insulin that works for up to 42 hours. The proprietary name, or how you might know it,